Outcome of postoperative radiation therapy for pediatric intracranial ependymoma: a single-institution review.
Ependymoma
Intracranial
Pediatrics
Radiotherapy
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
30
10
2018
accepted:
07
05
2019
pubmed:
17
6
2019
medline:
11
11
2020
entrez:
17
6
2019
Statut:
ppublish
Résumé
To report outcome of postoperative radiotherapy (RT) in both new and recurrent grade II and III intracranial ependymomas in children treated at Ramathibodi Hospital. Between 2006 and 2017, 24 pediatric intracranial ependymomas treated with postoperative RT were retrospectively reviewed. The median age at diagnosis was 44.5 months (range, 4-165 months). There were 14 (58%) males. Fourteen (58%) patients had infratentorial tumor. The median maximal diameter of tumor at diagnosis was 4.45 cm (range, 2.2-10 cm). Fourteen (58%) patients had anaplastic tumor. Gross total resections were performed in 14 (58%) patients. The median prescribed dose was 54 Gy (range, 45-60 Gy). The median total treatment time was 43 days (range, 37-78 days). The median clinical follow-up time was 44.5 months (range, 1-146 months). There were nine recurrences, five of which occurred at the primary tumor site. The estimated 5-year progression-free survival rate was 56%. The estimated 5-year overall survival rate was 75%. Extent of resection was the only factor associated with improved progression-free survival and overall survival after univariate testing. Six from nine patients with recurrent diseases underwent further surgery or further RT. These six patients had better median overall survival than the three who did not. Acute complication was mostly transient and tolerable. No late radiation effect was found. Postoperative radiation is an effective treatment. GTR is associated with better PFS and OS. Aggressive salvage local treatments for recurrent patients can result in good overall survival. Longer follow-up is needed in account for late relapse.
Identifiants
pubmed: 31203397
doi: 10.1007/s00381-019-04198-w
pii: 10.1007/s00381-019-04198-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1313-1321Références
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95
pubmed: 10661334
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):585-9
pubmed: 10837939
Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):757-61
pubmed: 11172959
Am J Clin Oncol. 2002 Apr;25(2):117-22
pubmed: 11943886
Pediatr Blood Cancer. 2004 May;42(5):457-60
pubmed: 15049020
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1336-45
pubmed: 15050308
J Clin Oncol. 2004 Aug 1;22(15):3156-62
pubmed: 15284268
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):387-91
pubmed: 15667957
J Neurosurg. 2005 Apr;102(4):629-36
pubmed: 15871504
Cancer. 2007 Jul 15;110(2):432-41
pubmed: 17559078
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):987-93
pubmed: 18258381
Pediatr Blood Cancer. 2009 Jan;52(1):65-9
pubmed: 19006249
Lancet Oncol. 2009 Mar;10(3):258-66
pubmed: 19274783
J Neurooncol. 2011 Dec;105(3):583-90
pubmed: 21637963
J Neurooncol. 2012 Jan;106(2):367-75
pubmed: 21826561
Pediatr Blood Cancer. 2012 Dec 15;59(7):1183-9
pubmed: 22949057
Neuro Oncol. 2016 Oct;18(10):1451-60
pubmed: 27194148
J Neurooncol. 2017 Oct;135(1):201-211
pubmed: 28733870
Acta Oncol. 2018 May;57(5):644-648
pubmed: 29239262